Category Patents/Designs/Trade Secrets

G7, In Japan, Put Their Heads Together Over Crises

Eight ministerial meetings have prepared a fat stack of paper, the “sherpas” have nearly concluded their work, and civil society once more has passed its own resolution on how they propose to tackle the most daunting global problems. Now it's time for the G7 leaders' roundtables – and the photo ops in Ise-Shima, Japan. For two days, the heads of state of Canada, France, Germany, Italy, Japan, the United Kingdom and the United States will talk on trade, foreign policy, climate change and energy. And maybe some digital, R&D and intellectual property issues.

Leaked EU Document Lays Out Major Evaluation Of EU Drug Pricing

The 28 European Union member governments are preparing to request the European Commission to conduct an in-depth evaluation of the availability and affordability of EU medicinal products that could lead to changes in R&D and pricing models. An apparent first-of-its-kind, the assessment would look at market and data exclusivity, supplementary protection certificates, and intellectual property issues, according to an alleged copy of the draft Council conclusions obtained by Intellectual Property Watch.

Innovation And Access: Fission Or Fusion? Interview With Tim Wilsdon, CRA Vice President

In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Tim Wilsdon, Vice President, CRA.

Unaffordable Medicines Now Global Issue; System Needs Change, Panellists Say

At a side event to this week’s annual World Health Assembly, a member of the Netherlands Ministry of Health delivered an unexpected speech on access to medicines, calling for more clarity in the setting of medicine prices, looking inside and outside of the patent system for solutions, and praising de-linkage. Other panellists viewed partnerships as a key ingredient to fill research and development gaps. And a representative from the Gates Foundation advised against a hasty switch to new system.

Countries ‘Disappointed’ With WHO Reform Progress

The World Health Organization secretariat this week reported to its member states on progress made in implementing sweeping programmatic, governance, and management reforms. The report? WHO has made progress, but there is still a long way to go. Member states, meanwhile, used the opportunity to express concern about the way it is going.

Initiative To Find New Antibiotics Launched At WHA

A new initiative seeking to develop new antibiotic treatments is being launched today at the annual World Health Assembly. The Global Antibiotic Research and Development (GARD) is a partnership between the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi).

US High Court To Consider IP Protection For Clothing Design

Fashion in the US generates over $330 billion in annual revenues, but it is more than a business. Fashion is a well-recognized art, displayed in numerous museum exhibitions throughout the world. This art, however, receives little IP protection in the US. But a case before the US Supreme Court could change that.

WHO Director Advocates Strong Health Systems, Warns Against Profit-Oriented Mechanisms

The World Health Assembly opened today with World Health Organization Director General Margaret Chan repeating that this year has a record number of agenda items and over 3,000 participants. She slapped at profit-seeking mechanisms leading to "slow-motion disasters," which put economic interests above concerns about well-being. In particular, she underlined the lack of research and development for antimicrobial treatments and the rise of chronic non-communicable diseases.